Clinical Trial Update: 18F-Fluciclovine PET/CT in Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating 18F-fluciclovine PET/CT imaging in patients with multiple myeloma, including newly diagnosed and relapsed/refractory case…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• And or Refractory Multiple Myeloma
• Multiple Myeloma

Drugs mentioned

• Axumin (fluciclovine F-18)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM) | Phase 2 | Status: RECRUITING